Medicinal composition containing amlodipine, ACE inhibitor and stains

A technology of amlodipine and levamlodipine, which is applied in the field of medicine and can solve unsatisfactory problems

Inactive Publication Date: 2010-02-10
王丽燕
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the antihypertensive effect of the compound preparation is obvious, it is still unsatisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing amlodipine, ACE inhibitor and stains
  • Medicinal composition containing amlodipine, ACE inhibitor and stains
  • Medicinal composition containing amlodipine, ACE inhibitor and stains

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0107] Embodiment 1: Levoamlodipine besylate, lisinopril and atorvastatin calcium tablet

[0108]

[0109]

[0110] Preparation:

[0111] (1) Granulation of atorvastatin calcium granules

[0112] Step 1. Pass various solid raw and auxiliary materials through No. 5 to No. 6 sieves, and set aside;

[0113] Step 2, dissolving polysorbate 80 in purified water at 45°C to 60°C, adding hydroxypropyl cellulose, and cooling the solution to room temperature;

[0114] Step 3, mixing atorvastatin calcium, calcium carbonate, microcrystalline cellulose, precrosslinked starch, crospovidone and croscarmellose sodium in a granulator;

[0115] Step 4. Mix the powder mixture from step 3 and the solution from step 2 in the granulator, and stir while adding to make a suitable soft material. If necessary, adjust its pH to 5.5-10.0. Use No. 2 Sieve to make wet granules;

[0116] Step 5, dry the granules in the drying equipment, sieve the granules with No. 2 sieve after drying, and finally ...

Embodiment 2

[0122] Embodiment 2: levamlodipine besylate, quinapril hydrochloride and simvastatin capsules

[0123]

[0124]

[0125] Preparation:

[0126] (1) Granulation of Simvastatin Granules

[0127] Step 1. Pass various solid raw and auxiliary materials through No. 5 to No. 6 sieves, and set aside;

[0128]Step 2, dissolving polysorbate 80 in purified water at 50°C, adding hydroxypropyl cellulose, and cooling the solution to room temperature;

[0129] Step 3, mixing simvastatin, calcium carbonate, microcrystalline cellulose, precrossified starch, sodium lauryl sulfate and croscarmellose sodium in a granulator;

[0130] Step 4. Mix the powder mixture from step 3 and the solution from step 2 in the granulator, and stir while adding to make a suitable soft material, and adjust its pH value to 5.5-10.0 if necessary; use No. 2 Sieve to make wet granules;

[0131] Step 5, dry the granules in the drying equipment, sieve the granules with No. 2 sieve after drying, and finally make ...

Embodiment 3

[0137] Embodiment 3: Amlodipine besylate, imidapril hydrochloride and pitavastatin calcium dispersible tablets

[0138]

[0139] Preparation:

[0140] (1) preparation of pitavastatin calcium microcapsules

[0141] Step A, pass various solid raw and auxiliary materials through No. 5 to No. 6 sieves respectively, and set aside;

[0142] Step B. Dissolve gelatin and gum arabic in purified water respectively, stir to make them fully dissolved, add pitavastatin calcium and cross-linked carboxymethyl cellulose sodium to gum arabic, and ultrasonically emulsify for 45 minutes, and gelatin solution and gum arabic Mix the gum solution into a three-necked flask, control the stirring speed to 200-400rpm, heat in a water bath, keep the temperature at 45°C-50°C, adjust the pH value of the system to 3.5-4.0, react for 55 minutes, and lower the temperature of the system to 2°C -8°C, add formaldehyde with a mass concentration of 25% and a glutaraldehyde solution with a mass concentration ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicinal composition. The composition comprises 1) any one of the following two ingredients: a) levamlodipine or pharmaceutically accepted salt thereof, or b) amlodipine orpharmaceutically accepted salt thereof; 2) ACE inhibitor (ACEI) or pharmaceutically accepted salt thereof; 3) stains or pharmaceutically accepted salt thereof; and 4) pharmaceutically accepted vector, wherein the amlodipine is selected from levamlodipine beaylate and amlodipine besylate; the ACEI is selected from lisinopril, quinapril, imidapril or pharmaceutically accepted salt thereof; and thestains is selected from atorvastatin, simvastatin, pravastatin or pharmaceutically accepted salt thereof. The composition is used for treating various high blood pressure accompanied with or not accompanied with hyperlipidaemia, angina and atherosclerosis, can treat or prevent heart cerebrovascular diseases related to high blood pressure, and improves the compliance of patient administration.

Description

technical field [0001] The present invention relates to a novel pharmaceutical composition, which specifically comprises: [0002] (1) Containing either of the following two types: (a) levamlodipine or a pharmaceutically acceptable salt thereof or (b) amlodipine or a pharmaceutically acceptable salt thereof, (2) vascular Tensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, (3) statins or pharmaceutically acceptable salts thereof, and (4) pharmaceutically acceptable carriers belong to the technical field of medicine. Background technique [0003] Due to the development of social economy and the change of people's lifestyle, the prevalence rate of hypertension in our country shows a continuous growth trend. According to the results of the national nutrition and health status survey in 2002, the prevalence rate of hypertension among adults in my country reached 18.8%. 160 million hypertensive patients. At present, one person dies of cardiovascular ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61P9/12A61P3/06A61P9/10A61P9/00A61P3/10A61P27/06A61K31/4422
Inventor 王丽燕
Owner 王丽燕
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap